Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Cash from Financing Activities (2022 - 2025)

Historic Cash from Financing Activities for BioXcel Therapeutics (BTAI) over the last 4 years, with Q3 2025 value amounting to $37.5 million.

  • BioXcel Therapeutics' Cash from Financing Activities rose 816696.04% to $37.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $55.1 million, marking a year-over-year increase of 5981.4%. This contributed to the annual value of $36.7 million for FY2024, which is 3822.49% up from last year.
  • BioXcel Therapeutics' Cash from Financing Activities amounted to $37.5 million in Q3 2025, which was up 816696.04% from $137000.0 recorded in Q2 2025.
  • In the past 5 years, BioXcel Therapeutics' Cash from Financing Activities ranged from a high of $37.5 million in Q3 2025 and a low of $50000.0 during Q4 2022
  • Over the past 4 years, BioXcel Therapeutics' median Cash from Financing Activities value was $4.8 million (recorded in 2024), while the average stood at $12.0 million.
  • Within the past 5 years, the most significant YoY rise in BioXcel Therapeutics' Cash from Financing Activities was 816696.04% (2025), while the steepest drop was 9741.7% (2025).
  • BioXcel Therapeutics' Cash from Financing Activities (Quarter) stood at $50000.0 in 2022, then skyrocketed by 4146.0% to $2.1 million in 2023, then skyrocketed by 101.41% to $4.3 million in 2024, then skyrocketed by 777.74% to $37.5 million in 2025.
  • Its last three reported values are $37.5 million in Q3 2025, $137000.0 for Q2 2025, and $13.2 million during Q1 2025.